| Cash Flow | 2025-09-30 |
|---|---|
| Net cash provided by investing activities | 0 |
| Stock based compensation expense - issuance of common stock for services rendered | 0 |
| Amortization of financing costs | 0 |
| Accretion of unearned loan discount | 0 |
| Accretion of loan premium | 0 |
| Change in fair value of derivative liabilities | 0 |
| Net loss | -5,087,557 |
| Stock based compensation - restricted stock units and restricted shares | 270,559 |
| Stock based compensation expense - stock options | 268,388 |
| Non-cash lease expense from right-of-use assets | 18,253 |
| Grant receivable | -1,924,246 |
| Prepaid and other current assets | -176,013 |
| Accounts payable and accrued expenses | -633,956 |
| Operating lease liabilities | -17,164 |
| Amortization of intangible assets | 57,344 |
| Net cash used in operating activities | -3,023,874 |
| Payment of loan premium | 0 |
| Net proceeds from issuance of common stock | 10,457,629 |
| Net cash provided by (used in) financing activities | 10,457,629 |
| Net change in cash and cash equivalents | 7,433,755 |
| Cash and cash equivalents at beginning of period | 17,544,547 |
| Cash and cash equivalents at end of period | 24,978,302 |
BIOVIE INC. (BIVI)
BIOVIE INC. (BIVI)